Content
Summary
Healthcare System Structure
The NHS
The NHS in England
Primary Care in England
PCT Prescribing Budgets: 'The Drugs Bill'
Local Pharmaceutical Services (LPS) in England
Secondary Care (Hospitals) in the UK
The NHS in Scotland
The NHS in Wales
LHBs
The NHS in Northern Ireland
Classification and Supply of Medicines in the UK
Nurse Prescribers in the UK
Pharmacist Prescribers (Supplementary Prescribing) in the UK
The Pharmaceutical Market?
Data for England
Data for England and Wales
Data for Wales
Data for Scotland
Data for Northern Ireland
Pharmaceuticals and Tax
The Pharmaceutical Price Regulation Scheme (PPRS)
Annual Financial Returns (AFRs)
Allocation of Costs and Capital
Limitation of Costs and Assets
Company Profit Cap
R&D Allowance
Marketing Allowance
Information Allowance
New Product Pricing
Products Sold On
Transfer Prices
Other Provisions
Arbitration
Prices Changes for Pharmaceuticals
Pharmaceutical Reimbursement
Dispensing Doctors
Personal Administration GP Claims
Local Supply or National FP10 Routes
Prescribing Information
The PSNC
Contractors in Scotland
Hospital Sales
OTC Price Regulation
Abolition of Resale Price Maintenance (RPM) in May 2001
Size of the UK OTC Medicines Market
Restrictions Removed on Advertising OTC Products
Reclassification (Switching)
Online Directory of OTC Products
Control of Pharmaceutical Expenditure
The PCA System
The Indicative Prescribing Scheme (IPS)
Economic Evaluation
The NICE
The HTBS
The SMC
Recent NICE Guidance and Decisions
Recent NICE Citizens Council Report
The Limited List ('Blacklisted' Products), and 'The Grey List'
Patient Co-Payment
What is the Effect of Generic Drugs?
The Drug Tariff
Maximum Price Scheme and Generics
Future Transfer of 'Standard' Branded Generics to the New Payment Arrangements for Generic Medicines
NHS Legal Action Against Anti-Competitive Price-Fixing
Pharmaceutical Wholesaling
Wholesale Margins
Pharmacy Finance and Margins
Control of Entry Restrictions Revised
New Community Pharmacy Contract
Payments for PCTs
Formula for Future Years
Funding for the New Essential Services
Global Sum Payments
Practice Payments
Protected Payments
Practice Payments
Exit Payments
LPS
ESPS Pharmacies
Impact of Parallel Imports
Future Developments
- A UK General Election in 2005: Re-Election of the Labour Government, and a Subsequent Decrease in the Share of the NHS Budget for Medicines
- The UK Government Cabinet Office May Review The NHS Drug Tariff, NHS Medicine Procurement, Generic Medicine Substitution, and the Control of Entry Regulations, in 2005
- Primary Care Trusts (PCTs) in England Will Receive 135bn in 2006/07 and 2007/08
- Increased Involvement of the European Commission and the European Parliament in the Pharmaceutical Industry and Healthcare Policy; and the Introduction of a Possible Single European Price
- The Possibility of the EU Allowing Pharmaceutical Companies to Set Prices for Medicines Ineligible for Government-Controlled Pricing and Reimbursement
- The Impact of the Accession of 10 New EU Member States in May 2004; Further Cost Containment: Cheaper Branded and Generic Drugs, and More Parallel Imports
- GlaxoSmithKline (GSK) Will Increase the Cost to Pharmacies of its Best-Selling Medicines from 1 April 2005, by Removing the 12% Discount it Gives on Drugs Where it Still Holds a Patent
- Pricing Reforms for Reimbursed Generic Medicines: Simplification of Drug Tariff Rules
- More POM to OTC P Medicine, and OTC P to OTC GSL Reclassifications ('Switches')
- More Prescribing by Nurse Prescribers and Supplementary Pharmacist Prescribers
- The New Community Pharmacy Contract Effective From April 2005
- Electronic Transmission of Prescriptions (ETP) will Begin in Early 2005
- Merger of the PPA into a new NHS Business Services Authority in October 2005
- The Application of VAT to Personally Administered Drugs and Appliances (in the Course of Treatment) is currently Under Appeal
Useful Contacts
Abbreviations used
About Urch Publishing
List of Figures
Figure 1 PPA System for Calculation of Reimbursements and Remuneration to Dispensers of Drugs in England
Figure 2 Reimbursement of Items on an FP10 Prescription Form
List of Tables
Table 1 NHS Expenditure on Medicines per Person in the UK
Table 2 Definitions of Prescribing Costs
Table 3 PPA Payments to Contractors
Table 4 Example of Timing of Reimbursement by PPA to Pharmacists
Table 5 The UK Drug Tariff for Generic Medicines
Table 6 Funding for the New Community Pharmacy Contract in England for 2005/6
Table 7 Funding for the New Community Pharmacy Contract in England 2005/6
Table 8 Annual Establishment Payments to Contractors in the Community Pharmacy Contract for 2005/06
Table 9 Practice Payments to Pharmacies Dispensing at Least 1,100 Items per Month in the Community Pharmacy Contract for 2005/06
Table 10 Summary of Pharmaceutical Cost-Containment Measures in the UK
|
